ArticleInternational journal of molecular sciences2025
Low Expression of UBE2Z, a Target Protein of miR-500a, Is Associated with Poor Prognosis in Triple-Negative Breast Cancer.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) exhibits diverse histological and molecular characteristics. TNBC patients also have the poorest prognoses among those with various breast cancer subtypes, and no effective treatment strategy has been established for TNBC beyond non-specific chemotherapy. Recent studies have reported that the dysregulation of miRNAs is associated with tumor behavior, prognosis, and treatment responses in TNBC patients. Therefore, this study was conducted to identify miRNAs and key target proteins potentially associated with TNBC prognosis. Fresh-frozen tissue from relapsing and non-relapsing TNBC cases was examined for differentially expressed miRNAs using the Affymetrix GeneChip miRNA 4.0 array, while target genes and proteins were predicted using the miRwalk 2.0 database. The clinical significance of each differentially expressed miRNA was evaluated using the BreastMark database. Additional bioinformatics analyses were conducted to reveal associations with tumor-related signaling pathways; these analyses included protein-protein interaction network construction and Kyoto Encyclopedia of Genes and Genomes pathway annotation. Gene chip analysis identified three upregulated miRNAs (miR-500a, miR-501-3p, and miR-502-3p) and two downregulated miRNAs (miR-6798-5p and miR-7150) in patients with recurrence, and further bioinformatics analyses revealed that target proteins were significantly associated with cell cycle pathways. In addition, low expression of the miR-500a target protein UBE2Z was significantly associated with a poor prognosis. The expression levels of miR-500a and UBE2Z might be useful prognostic biomarkers in TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.